Log In
Print this Print this

buprenorphine (RBP-6000)

  Manage Alerts
Collapse Summary General Information
Company Indivior plc
DescriptionOnce-monthly injectable sustained-release formulation of buprenorphine using the Atrigel delivery system
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAddiction
Indication DetailsTreat opioid dependence
Regulatory Designation U.S. - Fast Track (Treat opioid dependence)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today